talactoferrin alfa has been researched along with Adenocarcinoma in 1 studies
talactoferrin alfa: recombinant human lactoferrin, an oral drug for treatment of refractory solid tumors; in Phase I trial 5/2006
Adenocarcinoma: A malignant epithelial tumor with a glandular organization.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thus, the inhibition of distant tumors by oral TLF seems to be mediated by an IFN-gamma-dependent enhancement of CD8(+) T- and NKT cell activity initiated within the intestinal mucosa." | 1.34 | Requirement for IFN-gamma, CD8+ T lymphocytes, and NKT cells in talactoferrin-induced inhibition of neu+ tumors. ( Blezinger, P; Cavallo, F; Curcio, C; Engelmayer, J; Forni, G; Pericle, F; Spadaro, M; Varadhachary, A, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Spadaro, M | 1 |
| Curcio, C | 1 |
| Varadhachary, A | 1 |
| Cavallo, F | 1 |
| Engelmayer, J | 1 |
| Blezinger, P | 1 |
| Pericle, F | 1 |
| Forni, G | 1 |
1 other study available for talactoferrin alfa and Adenocarcinoma
| Article | Year |
|---|---|
Requirement for IFN-gamma, CD8+ T lymphocytes, and NKT cells in talactoferrin-induced inhibition of neu+ tumors.
Topics: Adenocarcinoma; Administration, Oral; Animals; Antineoplastic Agents; CD8-Positive T-Lymphocytes; Fe | 2007 |